Targeted oncology Position Pu·MA System as a platform enabling high-fidelity 3D cell models, organoids, and spheroids for oncology research; highlight VLFS technology to streamline reagent exchange in tumor biology workflows, offering faster, more reliable data to oncology labs.

Toxicology focus Emphasize capabilities for toxicity testing workflows with flowchip media, metabolite, and reagent exchange efficiency to reduce assay variability and improve throughput for preclinical safety assessments.

Metabolomics edge Frame the system as enabling precise microfluidic control for metabolomics studies, enabling more consistent sample handling and data-driven decisions in metabolite profiling and biomarker discovery.

Bay Area presence Leverage San Francisco Bay Area location to engage regional biotech clusters, offer in-person demos, and partner with nearby contract research organizations and academic labs seeking advanced assay automation.

Small team agility Highlight the company’s nimble scale and innovation cadence as an advantage for early-adopter labs wanting customized support, rapid iterations, and tight collaboration on pilot projects.